Prelude Therapeutics Inc (NASDAQ:PRLD) has a beta value of 1.53 and has seen 0.2 million shares traded in the last trading session. The PRLD stock price is -30.77% off its 52-week high price of $6.80 and 68.08% above the 52-week low of $1.66. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.25 million shares traded. The 3-month trading volume is 137.86K shares.
The consensus among analysts is that Prelude Therapeutics Inc (PRLD) is Sell stock at the moment, with a recommendation rating of 3.00. 2 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 0 advising it as a Buy. 0 have rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Prelude Therapeutics Inc (NASDAQ:PRLD) trade information
Over the past 30 days, the shares of Prelude Therapeutics Inc (NASDAQ:PRLD) have changed -7.96%. Short interest in the company has seen 1.43 million shares shorted with days to cover at 7.84.
Wall Street analysts have a consensus price target for the stock at $8.5, which means that the shares’ value could jump 38.82% from current levels. The projected low price target is $3.0 while the price target rests at a high of $15.0. In that case, then, we find that the current price level is -188.46% off the targeted high while a plunge would see the stock lose 42.31% from current levels.
Prelude Therapeutics Inc (PRLD) estimates and forecasts
Figures show that Prelude Therapeutics Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 13.29% over the past 6 months, with this year growth rate of 8.42%, compared to 20.20% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -43.14% over the past 5 years. Earnings growth for 2024 is a modest 9.31% while over the next 5 years, the company’s earnings are expected to increase by 30.10%.
PRLD Dividends
Prelude Therapeutics Inc is expected to release its next earnings report in October this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Prelude Therapeutics Inc (NASDAQ:PRLD)’s Major holders
Insiders own 9.06% of the company shares, while shares held by institutions stand at 94.10% with a share float percentage of 103.48%. Investors are also buoyed by the number of investors in a company, with Prelude Therapeutics Inc having a total of 91.0 institutions that hold shares in the company. The top two institutional holders are ORBIMED ADVISORS LLC with over 10.91 million shares worth more than $41.56 million. As of 2024-06-30, ORBIMED ADVISORS LLC held 14.4043% of shares outstanding.
The other major institutional holder is BAKER BROS. ADVISORS LP, with the holding of over 10.12 million shares as of 2024-06-30. The firm’s total holdings are worth over $38.57 million and represent 13.3673% of shares outstanding.
